BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
2 Lo Re V. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment. Clin Infect Dis 2017;64:498-500. [PMID: 28172488 DOI: 10.1093/cid/ciw814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Garcia-Broncano P, Medrano LM, Berenguer J, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Guardiola JM, Crespo M, Quereda C, Sanz J, García-Gómez AB, Jimenez JL, Resino S; GESIDA 3603b Study Group. Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status. Cells 2018;7:E196. [PMID: 30400258 DOI: 10.3390/cells7110196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS 2016;11:191-200. [PMID: 26720550 DOI: 10.1097/COH.0000000000000241] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
5 Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, Hull M, Chia J, Hogg RS, Moodie EE, Klein MB; Canadian Observational Cohort (CANOC) Collaboration. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis 2017;17:246. [PMID: 28376824 DOI: 10.1186/s12879-017-2350-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
6 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 de Miguel-Díez J, López-de-Andrés A, Jiménez-García R, Puente-Maestu L, Jiménez-Trujillo I, Hernández-Barrera V, Resino S, Álvaro-Meca A. Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012). PLoS One 2016;11:e0166421. [PMID: 27846297 DOI: 10.1371/journal.pone.0166421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Gowda C, Lo Re V 3rd. Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. Curr Hepatol Rep 2018;17:111-20. [PMID: 30294518 DOI: 10.1007/s11901-018-0394-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
9 Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferrière V, Walmsley SL, Cooper C, Gill MJ, Hull M, Moodie EEM, Klein MB; Canadian Co-Infection Cohort Investigators. Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. AIDS 2018;32:751-9. [PMID: 29369156 DOI: 10.1097/QAD.0000000000001750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
10 Vinhaes CL, Araujo-Pereira M, Tibúrcio R, Cubillos-Angulo JM, Demitto FO, Akrami KM, Andrade BB. Systemic Inflammation Associated with Immune Reconstitution Inflammatory Syndrome in Persons Living with HIV. Life (Basel) 2021;11:65. [PMID: 33477581 DOI: 10.3390/life11010065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang W, Lo Re V 3rd, Guo Y, Xiao H, Brown J, Park H. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. Aliment Pharmacol Ther 2020;52:1592-602. [PMID: 32931606 DOI: 10.1111/apt.16081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Zanni MV, Stone LA, Toribio M, Rimmelin DE, Robinson J, Burdo TH, Williams K, Fitch KV, Lo J, Grinspoon SK. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis 2017;4:ofx227. [PMID: 29226174 DOI: 10.1093/ofid/ofx227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
13 Postorino MC, Luciani F, Mangano C, Carpentieri MS, Scerbo P, Priamo A, Berardelli G, Marino R, Vallone A, Serrao N, Pisani V, Costa C, Terremoto A, Foti G, Cosco L, Calderazzo M, Corigliano D, Scordo P, Strazzulla A, Torti C; CalabrHIV Study Group. Demographical, Viro-Immunological, Clinical and Therapeutical Characteristics of HIV-Infected Patients in an "Epidemiologically Unexplored" Region of Italy (Calabria Region): the CalabrHIV Cohort. Mediterr J Hematol Infect Dis 2015;7:e2015054. [PMID: 26543523 DOI: 10.4084/MJHID.2015.054] [Reference Citation Analysis]